CAPRI Immunocellular Therapy
- Therapy Introduction· CAPRI Immunocellular Therapy is independently developed by Cedette Biotechnology and holds 100% proprietary intellectual property rights.
· This therapy is a non-genetically modified, autologous, polyclonal tumor-specific T cell population constructed from the patient's peripheral blood and selectively expanded through DC-mediated chain activation. It possesses sustained anti-tumor potential in vivo and holds promise for post-operative recurrence prevention. - Technical Essence· Autologous source: The starting material is the patient's peripheral blood (PBMC), avoiding invasive surgical tissue acquisition.
· Non-genetically modified: No viral vectors or gene editing are involved, and lymphodepletion is not required. This preserves the natural biological regulatory mechanisms of T cells, significantly reducing manufacturing costs and potential risks.
· Polyclonality: Unlike single-target approaches, CAPRI contains T cell clones recognizing multiple tumor antigens (TAA and neoantigens). - Core Process· Two-step chain activation: Uses proprietary technology to rapidly mature DCs and load tumor antigens, thereby clonally expanding tumor-specific T cells.
· Multi-cell synergy: Comprises CD8+ tumor-specific killer T cells, CD4+ helper T cells, and small numbers of NK and DC cells, forming a three-dimensional immune attack that enhances clinical efficacy.
· Short manufacturing cycle: The entire preparation process is completed within 7 days, allowing rapid response to clinical treatment windows and reducing contamination risks and production costs.
UCAR‑T Immunocellular Therapy
- Therapy Introduction· Built upon universal (allogeneic) CAR‑T technology, overcoming the individualized preparation limitations of autologous CAR‑T to achieve "off‑the‑shelf" therapeutic products.
· Dedicated to addressing two major challenges – autoimmune diseases and solid tumors – thereby expanding the application boundaries of CAR‑T therapy.
- Scalable & Standardized Manufacturing System· Fully closed automated production: Reduces manual intervention, improving process stability and safety.
· Modular process design: Supports rapid target switching (e.g., CD19, BCMA, CD22). New CAR gene modules can be quickly introduced into the established process and equipment platform, greatly enhancing R&D and production flexibility.
· Strict quality control: Ensures high batch‑to‑batch consistency through in‑process control of critical quality attributes, meeting global commercial standards. - Capacity & Cost Advantages
· High batch yield: Supports batch production of dozens to hundreds of patient doses, enabling scalable supply.
· Significantly reduced cost: Target cost per patient treatment is substantially lower than that of traditional autologous CAR‑T.
"· Off‑the‑shelf" availability: Eliminates patient‑specific manufacturing, reduces waiting time, and improves accessibility.
WeChat QR code
Global